RNA’s Rollercoaster: From Baby KJ to Funding Cuts

The RNA therapeutics and vaccine space is whipsawing between historic scientific wins and disruptive policy reversals. As RNA-delivered CRISPR technologies make headlines and mRNA cancer drugs attract big-name investors, U.S. funding pullbacks are casting a long shadow. CDMOs must decide now how to adapt—because the ground is shifting beneath their feet.

Recent Successes

• CRISPR milestone: In 2025, Baby KJ became the first patient cured of a rare genetic disorder using in vivo CRISPR delivered via lipid nanoparticle-encapsulated RNA—a major leap in precision medicine and RNA-based gene editing.

• Strand Therapeutics closed a $153 million Series B to develop programmable mRNA cancer therapies, with backing from Regeneron, Lilly, and Amgen.

• Moderna’s mRNA flu vaccine (mRNA‑1010) showed efficacy in adults 50+, with strong Phase 3 results prompting investor optimism.

• Arcturus’s self‑amplifying COVID-19 vaccine (Zapomeran) received regulatory approval in Japan and the EU.

• ~70% of active mRNA vaccine trials now target non-COVID indications—from oncology to immune disorders—signaling RNA’s mainstream adoption.

• This has drawn harsh criticism from scientists and public health officials, who warn it could delay pandemic preparedness and discourage innovation.

• Technological hurdles remain: RNA’s instability, delivery limitations, and degradation risks still constrain its therapeutic potential—especially in extrahepatic targeting and systemic delivery.

• Public perception risks: Political pushback could reignite skepticism around RNA—affecting adoption and clinical trial enrollment, particularly in the U.S.Public perception risks: Political pushback could reignite skepticism around RNA—affecting adoption and clinical trial enrollment, particularly in the U.S.

Why This Means for CDMOs

In the Short Term:

• Spike in oncology and CRISPR-related programs: Expect a rise in demand for lipid nanoparticle (LNP) formulation, precision delivery, and analytics—especially for non-viral gene editing tools like RNA-delivered CRISPR.

• Private funding replaces public projects: As U.S. government contracts dry up, CDMOs must pivot toward commercial biotech, big pharma, and international clients to fill the gap.

In the Long Term:

• Platform complexity will drive differentiation. CDMOs that can support multi-modal RNA platforms—mRNA, saRNA, circRNA, and RNA-delivered gene editing—will emerge as strategic partners.

• The delivery frontier becomes the new battleground. Expertise in developing scalable, targeted delivery systems for muscle, brain, and immune cells will become a core differentiator.

• Policy divergence creates regional dynamics. Global CDMOs or those with APAC/EU partnerships may find it easier to sustain growth if U.S. regulatory and funding volatility continues.

Bottom Line

• The success of Baby KJ and the rise of RNA-delivered CRISPR prove that RNA therapeutics are no longer “emerging”—they’re here.

• But the pullback in U.S. support threatens the pace of innovation and shifts the funding landscape toward private and global players.

• For CDMOs, this is a pivot point: those who invest in advanced delivery, analytics, and RNA manufacturing agility now will be best positioned to capture next-gen gene editing, oncology, and vaccine partnerships—regardless of where the funding originates.

Want help refining your message in this new market environment?
Contact Jeff Briganti

Setbacks and Challenges

• U.S. policy whiplash: HHS Secretary RFK Jr. abruptly canceled or restructured $500 million in federal mRNA contracts, including pandemic flu and bird flu projects.